Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.
暂无分享,去创建一个
R. Gibbs | S. Hilsenbeck | D. Wheeler | W. Whitehead | A. McGuire | Yaping Yang | S. Plon | C. Eng | Angshumoy Roy | K. Eldin | Tao Wang | M. Chintagumpala | F. Monzon | A. Adesina | M. Hicks | A. Jea | D. Lopez-Terrada | S. Scollon | Katie Bergstrom | S. Vasudevan | J. Nuchtern | Robin A. Kerstein | Stephanie Gutierrez | A. Petersen | A. Bavle | F. Lin | Norma M. Quintanilla | C. Mohila | S. Berg | J. Reid | D. W. Parsons | Uma Ramamurthy | D. Muzny
[1] H. Witt,et al. Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[3] A. Redig,et al. Basket trials and the evolution of clinical trial design in an era of genomic medicine. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Magalie S Leduc,et al. Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.
[5] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[6] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[7] R. Gibbs,et al. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients , 2014, Genome Medicine.
[8] Leslie G Biesecker,et al. Diagnostic clinical genome and exome sequencing. , 2014, The New England journal of medicine.
[9] Yuya Kobayashi,et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Gibbs,et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline , 2014, BMC Bioinformatics.
[11] Benjamin J. Raphael,et al. Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer , 2014, Nature Communications.
[12] Magalie S Leduc,et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.
[13] Emily H Turner,et al. Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.
[14] Manash S. Chatterjee,et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.
[15] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[16] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[18] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[19] Giovanni Parmigiani,et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.
[20] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[21] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[22] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[23] J. Opitz,et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility , 2012, Nature Genetics.
[24] R. Gibbs,et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities , 2011, Genome Biology.
[25] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[26] A. Byars,et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.
[27] R. Siebert,et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.
[28] Nazneen Rahman,et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma , 2009, Nature Genetics.
[29] K. Nathanson,et al. Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic , 2006, Cancer biology & therapy.
[30] Adopted on March. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.